Skip to content
Disability, Medical Health Aged Care

NDIS reform brings clarity for people at the end of life

Palliative Care Australia 2 mins read

People living with disabilities at the end of life now have more clarity around who provides the care and supports central to their quality of life.

“Over the last 12 to 24 months, we’ve been hearing from our members and other voices in the sector that people under 65 with disabilities linked to a life-limiting illness were being refused access to day to day living supports,” says Camilla Rowland, Chief Executive Officer, Palliative Care Australia (PCA).

“We are delighted that the recommendations in our recent submission to the NDIS supports review have been actioned; we hope the influence of this reform will soon start to make a difference in how some of our most vulnerable people experience life and death.”

Earlier this month, the Australian Government announced some important changes to the NDIS Act and the Rules supporting the Act.

Of most relevance for the palliative care sector and patients is the rule change that clearly defines state and territory health services as being responsible for providing specialist clinical palliative care services, and the NDIS as being responsible for funding functional disability related services.

“Prior to the rule change there was ambiguity, which left NDIS participants who are dying, in the middle of a funding battle between the NDIS and state and territory health systems, which too often left people without any funded support for their disability-related needs,” Ms Rowland says.

“Now that we have been able to establish clearer boundaries between state and federal systems, we hope to see better co-ordination between specialist clinical palliative care services, and the functional, non-clinical services funded by the NDIS; leading to better outcomes for NDIS participants and their loved ones.”

These changes are now reflected on the NDIS website.

“While this is welcome reform, the NDIS was never intended to fill this gap, and gaps still remain for many people with life limiting illness when it comes to accessing timely care and support,” Ms Rowland says.

“The services need to be there for this system to work and provide the care people need at the end of life, and too often that is not the case.”

“Governments need to work out how people under 65 with disabilities linked to a life-limiting illness, can access basic care and support at home in their final months and weeks.

“If we can’t solve this problem, more and more people will be admitted to hospital unnecessarily, at much greater expense.

“We will have more to say about this critical gap in services in the lead up to the Federal Election.”

If you have an experience to share about lack of access to palliative care or disability support, please contact PCA via pca@palliativecare.org.au


Contact details:

Ian Campbell

P: 0417 482 171

E: Ian.Campbell@palliativecare.org.au

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.